The safety and efficacy of these investigational agents and/or uses have not been established. There is no guarantee that they will become commercially available.
aFor participants with previously untreated AML who are ineligible for intensive chemotherapy. bPatient population includes those with R/R NHL, including R/R DLBCL. ciMMagine-1 is being codeveloped with Arcellx. dIn collaboration with Merck. eIn collaboration with Alliance Foundation Trials, LLC. fA Phase 3 Asian Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice (TPC) in Subjects With Hormonal Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer (MBC) Who Have Failed at Least 2 Prior Chemotherapy Regimens. gMagro + chemo and Magro + SG. hEVOKE-03 is being operationalized by Merck. iIn collaboration with Arcus Biosciences. jARC-10: Dom + Zim vs Pembro. kPACIFIC-8: Durva + Dom vs Durva + placebo. lIn collaboration with AstraZeneca. mARC-7: Zim ± Dom ± Etruma. nMagro + Pembro + chemo and Pembro + chemo and Magro + Zim + chemo. oSTAR-221 is being operationalized by Arcus Biosciences. pSTAR-221: Dom + Zim + FOLFOX vs Nivo + FOLFOX. qARC-21/EDGE-Gastric: (1L) Dom + Zim + chemo, Zim + chemo and (2L) Dom + Zim, Zim + Quemli. rARC-9: Etruma + Zim + FOLFOX vs FOLFOX, Etruma + Zim + FOLFOX vs Rego, and Etruma + Zim + Quemli. sMagro + Bev + FOLFIRI. tARC-8: Quemli + Zim + Gem/Nab-pac. umNSCLC, mSCLC, mHNSCC, mEC. vPatient population includes those with moderate hepatic impairment. wSelected programs listed are optionable partner programs. Gilead has not opted into these programs unless otherwise noted.
1L, first line; 2L, second line; 3L, third line; A2aR/A2bR, adenosine 2a receptor/adenosine 2b receptor; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; Bev, bevacizumab; BC, breast cancer; BCL, B-cell lymphoma; CAR-T ddBCMA, autologous anti-B-cell maturation antigen (BCMA) Chimeric Antigen Receptor (CAR)T-cell therapy; CCR8, chemokine receptor 8; CD19/20/47/73, cluster of differentiation 19/20/47/73; Chemo, chemotherapy; CLL-1, C-type lectin-like molecule-1; CRC, colorectal cancer; DLBCL, diffuse large B-cell lymphoma; Doce, docetaxel; DGKα, diacylglycerol kinase alpha; Dom, domvanalimab; Durva, durvalumab; EC, endometrial cancer; Etruma, etrumadenant; FL, follicular lymphoma; FOLFIRI, FOLinic acid-Fluorouracil-IRInotecan regimen; FOLFOX, FOLinic acid-Fluororuracil-OXaliplatin regimen; Gem/Nab-pac, gemcitabine/nab-paclitaxel; GI, gastrointestinal; GU, genitourinary; HNSCC, head and neck squamous cell carcinoma; IO, immuno-oncology; ITIM, immunoreceptor tyrosine-based inhibitory motif; LBCL, large B-cell lymphoma; m, metastatic; Magro, magrolimab; MCL-1, myeloid cell leukemia-1; MM, multiple myeloma; NCT, national clinical trial; Nivo, nivolumab; NHL, non-Hodgkin lymphoma; NSCLC, non-small cell lung cancer; PARPi, poly (adenosine diphosphate [ADP]) ribose polymerase (PARP) inhibitor; Pembro, pembrolizumab; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; PDAC, pancreatic ductal adenocarcinoma; PK, pharmacokinetics; Quemli, quemliclustat; Rego, regorafenib; R/R, relapsed/refractory; SG, sacituzumab govitecan; TIGIT, T cell immunoreceptor with immunoglobulin and ITIM domains; TNBC, triple-negative breast cancer; TROP2, trophoblast cell-surface antigen 2; UC, urothelial cancer; Zim, zimberelimab.
1. Gilead Sciences Inc. Third Quarter 2023 Earnings Call. November 7, 2023. Available at: https://s29.q4cdn.com/585078350/files/doc_financials/2023/q3/GILD-Q323-Earnings-Presentation-7-November-2023.pdf 2. ClinicalTrials.gov website.